Antibe Therapeutics Inc. is a Canada-based company that originates, develops and out-licenses pharmaceuticals that are improved versions of existing drugs. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. The Company's lead compound, ATB-346, combines hydrogen sulfide (H2S) with naproxen, which is an approved, marketed and off patent non-steroidal anti-inflammatory drug (NSAID). The Company has conducted multiple pre-clinical studies, combining the attributes of H2S with naproxen, which have demonstrated that ATB-346, which has therapeutic efficacy that is equal to or greater than that of naproxen while demonstrating an improved side-effect profile versus naproxen and other commonly used NSAID treatments for pain associated with, amongst other conditions, osteoarthritis. Additionally, the Company investigates other assets in its pipeline, as well as additional development opportunities to which it has access.